|
Bitter melon: MAP30, a protein isolated from bitter melon extract, has been reported to possess anti-neoplastic effects in vitro. These effects have been attributed to the reduced expression of growth factor receptors, such as the transmembrane tyrosine kinase receptor HER2 (also known as neu or c-erb-2), which has been implicated in breast cancer. MAP30 was originally identified as a single chain ribosome inactivating protein (SCRIP), but its in vitro antineoplastic activities appear to be unrelated to its effect on ribosomes. The MAP30 gene has been cloned and expressed, and the recombinant protein re-MAP30 possesses similar properties in vitro as native MAP30. However, the antineoplastic effects of MAP30 (or bitter melon) have not been studied in humans.Avoid if allergic to bitter melon or members of the Curcurbitaceae (gourd or melon) family, including Persian melon, honeydew, casaba, muskmelon, and cantaloupe. Read more
|
Learn
